Shares of Healthcare Triangle dropped 8.6% to $1.86 after the micro-cap health-tech firm revealed it had rewritten two key agreements to pay in stock instead of cash, triggering fresh fears that existing shareholders could see their ownership stakes virtually wiped out.
• Paying for an Acquisition With Paper, Not Cash, Signals a Liquidity Crunch
On June 25, HCTI amended its January 2026 deal to buy Spanish AI firms through its Teyame AI subsidiary, replacing the original cash-and-stock terms with $12 million in restricted common stock and 18,000 shares of new Series C preferred stock, each convertible into 430 common shares.
The Teyame deal alone could release up to 11.87 million new common shares. When a company shifts acquisition payments from cash to equity, it typically means the balance sheet cannot support the outflow — a red flag for a firm that just raised $3.6 million through deeply discounted convertible notes weeks earlier.
• A Legacy Obligation Got Settled With More Shares
Separately, HCTI agreed to issue 2,828,167 common shares to SecureKloud Technologies as a make-whole settlement for Series B preferred stock that had lost much of its conversion value after a 1-for-60 reverse split in February. This effectively compensates an old partner for value destruction caused by HCTI's own capital restructuring — and current shareholders foot the bill through dilution.
• The Math Is Alarming: Share Count Could Multiply Roughly 12×
HCTI had just 2,027,783 common shares outstanding as of June 8. Between the 2.8 million SecureKloud settlement shares, up to 11.9 million Teyame shares, and up to 9.4 million shares from convertible-note conversions, the proposals before shareholders could add tens of millions of new shares.
A $50 million equity line of credit and automatic annual increases to the employee stock plan add further dilution overhang.
• A Proxy Vote Will Decide How Deep the Dilution Goes
Nasdaq rules require shareholder approval before issuing stock exceeding 20% of the pre-deal share count, and HCTI acknowledges the Teyame securities far exceed that threshold.
The upcoming annual meeting bundles the Teyame approval with votes on the settlement shares, the equity line, and convertible-note issuances — concentrating every dilutive decision into a single ballot. Shareholders face a stark choice: approve massive dilution or potentially kill the deals HCTI says are critical to its growth strategy.